Subject population
Adults ≥18 with a clinical diagnosis of heart failure with reduced ejection fraction (HFrEF)
Inclusion criteria
- Aged ≥18
- Evidence in the GP record of Left Ventricular Systolic Dysfunction (LVSD)
- New York Heart Association (NYHA) class ≥II
Exclusion criteria
- Diastolic dysfunction with EF>50% or preserved left ventricular function
- Supplementary CoQ10 intake within the last 6 weeks
- Current warfarin use (CoQ10 may reduce the anticoagulant effect of warfarin)
- Allergy to soy
- Allergy to peanuts
- Currently involved in another interventional clinical trial
- Unable to provide informed consent
- Unwilling to take part due to diet choices (capsules contain halal bovine gelatine)
- Women only: pregnant, breastfeeding